Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Zhuoya Huang"'
Autor:
Hongyu Zhang, Zhuoya Huang, Liuliu LV, Yuye Xin, Qian Wang, Feng Li, Lina Dong, Changxin Wu, Philip W. Ingham, Zhonghua Zhao
Publikováno v:
Open Biology, Vol 12, Iss 8 (2022)
Cilia are organelles for cellular signalling and motility. Mutations affecting ciliary function are also associated with cilia-related disorders (ciliopathies). The identification of cilia markers is critical for studying their function at the cellul
Externí odkaz:
https://doaj.org/article/4d9cc8d1af2649909f77cefea14d0f8f
Autor:
Juan Wu, Ru Chen, Huiqing Shen, Ting Yan, Yu Qian, Yaping Zhang, Zhuoya Huang, Pengzhou Kong, Min Pang, Xinri Zhang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Ivosidenib is an isocitrate dehydrogenase mutant inhibitor that the US Food and Drug Administration recently approved for the treatment of leukemia. Studies suggested that ivosidenib may inhibit the progression of non-small cell lung cancer (NSCLC).
Externí odkaz:
https://doaj.org/article/ca81f9c4634f4a2a8ef38df58cc927dc
Publikováno v:
Environment and Planning A: Economy and Space. 53:1851-1854
As an extension of public space, the public transport system in modern society is an arena for cross-group interactions. Uncovering social segregation in public transport space is an essential step in shaping a socially sustainable transport system.
Autor:
null Hongyu Zhang, null Zhuoya Huang, null Liuliu LV, null Yuye Xin, null Qian Wang, null Feng Li, null Lina Dong, null Changxin Wu, null Philip W. Ingham, null Zhonghua Zhao
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf2bb3a5820d5e2a9840fab0f5fc6274
https://doi.org/10.1098/rsob.220104/v2/response1
https://doi.org/10.1098/rsob.220104/v2/response1
Autor:
Pengzhou Kong, Huiqing Shen, Yaping Zhang, Ru Chen, Xin-ri Zhang, Juan Wu, Yu Qian, Min Pang, Zhuoya Huang, Ting Yan
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Ivosidenib is an isocitrate dehydrogenase mutant inhibitor that the US Food and Drug Administration recently approved for the treatment of leukemia. Studies suggested that ivosidenib may inhibit the progression of non-small cell lung cancer (NSCLC).
Publikováno v:
Bioengineered; 2022, Vol. 13 Issue 5, p13201-13212, 12p
Autor:
Ting Wen, Mingcheng Zhou, Changgeng Peng, Ruilong Xia, Liting Sun, Jinwen Jiang, Ming-Dong Zhang, Ran Qian, Zhuoya Huang
Publikováno v:
Progress in neurobiology. 202
Voltage-gated sodium channels (Navs) 1.7, 1.8, and 1.9 are predominately expressed in peripheral sensory neurons and are critical for action potential propagation in nociceptors. Unexpectedly, we found that expression of SCN9A, SCN10A, SCN11A, and SC
Autor:
Zhonghua Zhao, Zhuoya Huang
Publikováno v:
Mechanisms of Development. 145:S160
Publikováno v:
International journal of clinical and experimental pathology. 7(10)
Epstein-Barr virus (EBV) associated lymphoproliferative disease (LPD) are commonly derived from B-cells, however, it is becoming more and more apparently that EBV can also infect T-lymphocytes. Systemic EBV positive T-cell LPD of childhood is rare an